Acumen (United States)

Recent papers from Acumen (United States)

1. Inpatient Mortality and Risk Factors Among Hospitalized Medicare Beneficiaries Ages 65 and Older with COVID-19 Treated with COVID-19 Convalescent Plasma (CCP), During 2020-20212026
2. Respiratory Syncytial Virus Vaccine Effectiveness Among US Older Adults, 2023-2024 SeasonJAMA Network Open · 2026
3. Respiratory Syncytial Virus Vaccine Effectiveness in Medicare Beneficiaries Residing in Nursing HomesJAMA Internal Medicine · 2026
4. New approach methodologies for next-generation risk assessment of nanomaterials and nano-enabled productsNano Convergence · 2026
5. 62 Application of simple and robust in vitro pulmonary models to evaluate the safety of carbon-based lubricantsAnnals of Work Exposures and Health · 2026
6. Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical modelsThe Journal of Experimental Medicine · 2026
7. Epistemic Self-Assessment Without Model Confidence: An AI That Knows What It Doesn't Know2026
8. Continuous Memory Consolidation Without Retraining: Solving the Edge Bloat Problem Through Computational Sleep2026
9. Causal Imagination Without Language Generation: Forward Simulation Through Graph Traversal2026
10. Cross-Domain Transfer Learning in Developmental Knowledge Graphs Without Training2026
11. Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 yearsVaccine · 2026
12. Physician Antibiotic Prescribing Preferences in Community Acquired Pneumonia and Complicated Urinary Tract Infections: A National Discrete Choice ExperimentOpen Forum Infectious Diseases · 2025
13. P-1436. Respiratory syncytial virus vaccine uptake among Medicare fee-for-service beneficiaries, 2023-2025Open Forum Infectious Diseases · 2026
14. Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United StatesPLoS ONE · 2025
15. Validation of the US Food and Drug Administration's COVID‐19 Disease Severity Categorization for Use in Real‐World DataPharmacoepidemiology and Drug Safety · 2025
16. Validation of the US Food and Drug Administration's COVID‐19 Disease Severity Categorization for Use in Real‐World DataPharmacoepidemiology and Drug Safety · 2025
17. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 in Long-Term CareThe Journal of Infectious Diseases · 2025
18. Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United StatesPLoS ONE · 2025
19. Safety Monitoring of Bivalent COVID ‐19 mRNA Vaccines Among Recipients 6 Months and Older in the United StatesPharmacoepidemiology and Drug Safety · 2025
20. Lessons Learned From Characterizing Long COVID Among US Medicare BeneficiariesPharmacoepidemiology and Drug Safety · 2025